Metabolism
Oral β2-agonist targeting muscle metabolism shows promise for type 2 diabetes and obesity
Ti AI ṣe iroyin Àwòrán tí AI ṣe Ti ṣayẹwo fun ododo
Researchers at Karolinska Institutet and Stockholm University have developed an experimental oral drug that boosts metabolism in skeletal muscle, improving blood sugar control and fat burning in early studies without reducing appetite or muscle mass. Unlike GLP-1-based drugs such as Ozempic, the candidate acts directly on muscle tissue and has shown good tolerability in an initial clinical trial, according to the study authors.
Researchers at the University of Technology Sydney have created experimental compounds that prompt mitochondria to burn more calories safely. These mild mitochondrial uncouplers could offer a new approach to treating obesity without the deadly risks of past chemicals. The findings, published in Chemical Science, highlight potential benefits for metabolic health and aging.
Ti AI ṣe iroyin Ti ṣayẹwo fun ododo
A study in obese mice has found that the gut-derived hormone FGF19 can signal the brain to increase energy expenditure and activate fat-burning cells. Acting through the hypothalamus and the sympathetic nervous system, this mechanism enhances thermogenesis and cold tolerance and may help guide new treatments for obesity and diabetes.